25,000 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Acquired by Allianz Asset Management GmbH

Allianz Asset Management GmbH purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $198,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at $27,000. Tower Research Capital LLC TRC raised its position in shares of Day One Biopharmaceuticals by 911.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock worth $135,000 after buying an additional 9,603 shares during the period. Pallas Capital Advisors LLC acquired a new position in Day One Biopharmaceuticals in the first quarter valued at $87,000. Wealth Enhancement Advisory Services LLC purchased a new stake in Day One Biopharmaceuticals during the first quarter valued at about $88,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Day One Biopharmaceuticals during the fourth quarter valued at about $150,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, CFO Charles N. York II sold 4,282 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $26,805.32. Following the sale, the chief financial officer owned 265,231 shares in the company, valued at $1,660,346.06. This trade represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jeremy Bender sold 13,964 shares of the company’s stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $87,414.64. Following the completion of the transaction, the chief executive officer owned 145,737 shares of the company’s stock, valued at $912,313.62. This trade represents a 8.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,725 shares of company stock valued at $167,299 over the last 90 days. 6.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

DAWN has been the topic of a number of research reports. Wedbush restated an “outperform” rating and issued a $25.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. Needham & Company LLC dropped their target price on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $29.00.

Day One Biopharmaceuticals Price Performance

Shares of DAWN opened at $6.74 on Tuesday. Day One Biopharmaceuticals, Inc. has a 12 month low of $6.08 and a 12 month high of $16.76. The stock’s 50-day moving average is $6.71 and its two-hundred day moving average is $8.16. The stock has a market cap of $683.17 million, a PE ratio of -9.49 and a beta of -1.26.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.11. The firm had revenue of $30.76 million for the quarter, compared to analyst estimates of $30.28 million. Day One Biopharmaceuticals had a negative return on equity of 14.98% and a negative net margin of 42.66%. On average, research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.